Peptide library / Immune & defense / LTX-315
LTX-315
An oncolytic peptide injected into tumors to trigger an immune attack.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Melanoma and other solid tumors, with immunotherapySmall human studies
How it is thought to work
LTX-315 breaks open cancer cell membranes, releasing signals that recruit immune cells against the tumor.
What the evidence shows
Early trials reported immune activation in injected tumors. Data are limited to small studies.
Safety and unknowns
Injection site reactions and allergic-type reactions.
Regulatory status
Not approved.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Immune & defense
Murepavadin
In clinical trialsA first-in-class peptide antibiotic targeting Pseudomonas aeruginosa.
Nangibotide
In clinical trialsA TREM-1 inhibitor peptide tested in septic shock.
LL-37
Wellness and performanceThe only cathelicidin in humans, an antimicrobial and wound-healing peptide produced by skin and immune cells.
General information, not medical advice. Do not buy or inject unregulated peptides.